Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-7-2
pubmed:abstractText
Research into the toxic effects of antiretroviral therapy has made tremendous progress, particularly over the 5 years since the earliest descriptions of the lipodystrophy syndrome. In particular, the contribution of specific antiretroviral drugs to these toxicity syndromes is becoming clearer, along with their pathophysiological mechanisms. This knowledge can now direct research on host genetic factors that may significantly influence the risk of both short-term and long-term toxicities. At present, the genetic association with abacavir hypersensitivity appears sufficiently strong to consider pharmacogenetic testing in clinical practice, although further corroborative research is still needed. The future will see increasing use of both pharmacogenetics (the genetic basis for variation in the response to specific medications) and immunogenetics (the genetic basis for variation in the response to specific antigens). The identification of an increasing number of genetic associations with drug efficacy/toxicity may, or may not, result in widespread genetic testing, but it will certainly increase our understanding of the mechanisms of both desirable and adverse drug effects and inform drug development.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1462-0308
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
36-41
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?
pubmed:affiliation
Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth 6000, Western Australia.
pubmed:publicationType
Journal Article, Review